The growing pains of neoadjuvant trials for gastroesophageal carcinoma. Surgical Oncology

摘要

In this issue of the Annals of Surgical Oncology, Gaca et al. from Duke University Medical Center present a retrospective analysis of 101 patients receiving neoadjuvant chemoradiation followed by surgical resection for gastroesophageal junction (GEJ) carcinoma. The purpose of the study was to identify factors affecting the overall survival and disease-free survival (DFS) in patients receiving multimodality therapy for GEJ tumors. Almost 90% of the tumors were located in the distal esophagus, and all but five were adenocarcinoma. All patients underwent pretreatment staging with computed tomographic scanning of the chest and abdomen, and endoscopic ultrasonography (EUS) was performed in 39 patients.